21
Participants
Start Date
December 31, 2004
Primary Completion Date
November 30, 2006
Study Completion Date
August 31, 2013
Capecitabine (Xeloda)
Starting Dose 500 mg/m\^2 twice a day Days 1-14 of 21 Day Cycle.
DTIC-Dome (Dacarbazine)
Starting Dose 250 mg/m\^2 a day on Days 1-3 of 21 Day Cycle.
Gleevec (Imatinib Mesylate)
Starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
UT MD Anderson Cancer Center, Houston
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
M.D. Anderson Cancer Center
OTHER